Here are the Federal Register notice summary excerpts that might be of interest to you or others within your organization. Please see notices for complete details. Federal Register notices are for general information purposes only and should not be relied upon as a substitute for thorough regulatory assessment. All efforts are made to assure the accuracy and completeness of this information, but CHPA cannot guarantee the information. As a benefit of CHPA membership, recipients are asked not to forward or share this information outside of your company.
We are encouraged by the ongoing, bipartisan momentum behind this reform and look forward to seeing the legislation move forward in the House as well as the Senate.
Today, the United States Senate Health, Education, Labor and Pensions (HELP) Committee approved S. 2315, the Over-the-Counter Drug Safety, Innovation, and Reform Act by a 22-1 vote.
CHPA strongly supports the OTC Monograph System, but we believe that policy reforms could make the system more flexible, responsive, and accommodating to innovation.
Unlike other drugs subject to user fees, nonprescription drugs under the Monograph system are not subject to FDA approval prior to marketing. Many of these ingredients have been marketed for more than 40 years, with a long history of safe use. We must define value differently than industries subject to FDA approval prior to marketing.
CHPA issued the following statement following the Food and Drug Administration’s announcement of a public meeting to gather stakeholder input on the potential development of a user fee program for nonprescription monograph drugs.
CHPA appreciates the opportunity to provide comments on the FDA’s draft guidance for industry entitled “Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act Products”.
